WO2003094909A3 - Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease - Google Patents

Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease Download PDF

Info

Publication number
WO2003094909A3
WO2003094909A3 PCT/US2003/013689 US0313689W WO03094909A3 WO 2003094909 A3 WO2003094909 A3 WO 2003094909A3 US 0313689 W US0313689 W US 0313689W WO 03094909 A3 WO03094909 A3 WO 03094909A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
disease
intermittent claudication
prevention
treatment
Prior art date
Application number
PCT/US2003/013689
Other languages
French (fr)
Other versions
WO2003094909A2 (en
Inventor
Eyal S Ron
Original Assignee
Enos Pharmaceuticals Inc
Eyal S Ron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enos Pharmaceuticals Inc, Eyal S Ron filed Critical Enos Pharmaceuticals Inc
Priority to AU2003231252A priority Critical patent/AU2003231252A1/en
Publication of WO2003094909A2 publication Critical patent/WO2003094909A2/en
Publication of WO2003094909A3 publication Critical patent/WO2003094909A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for the treatment and prevention of intermittent claudication or Alzheimer's disease in a subject, comprising administering to a subject a formulation comprising a precursor of NO, e.g., L-arginine and a formulation comprising an agonist of eNOS, e.g., and HMG-CoA reductase inhibitor, or a formulation comprising both L-arginine and an HMG-CoA reductase inhibitor. The invention further provides that the formulations used to treat or prevent intermittent claudication or Alzheimer's disease contain at least one controlled release agent. In a further embodiment, the production of NO is substantially uniform over a prolonged period of time.
PCT/US2003/013689 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease WO2003094909A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003231252A AU2003231252A1 (en) 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37968402P 2002-05-09 2002-05-09
US60/379,684 2002-05-09

Publications (2)

Publication Number Publication Date
WO2003094909A2 WO2003094909A2 (en) 2003-11-20
WO2003094909A3 true WO2003094909A3 (en) 2004-04-01

Family

ID=29420551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013689 WO2003094909A2 (en) 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003231252A1 (en)
WO (1) WO2003094909A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (en) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Polymorph
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (en) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 The salt form of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX341025B (en) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Combination therapy.
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
PL2731947T3 (en) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors

Also Published As

Publication number Publication date
WO2003094909A2 (en) 2003-11-20
AU2003231252A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
WO2003094909A3 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0223040D0 (en) Therapeutic compounds
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2004089353A8 (en) Methods for treatment of parkinson's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
GB0005251D0 (en) Therapeutic compounds
PL347469A1 (en) Use of certain drugs for treating nerve root injury
MXPA05004290A (en) Sustained release l-arginine formulations and methods of manufacture and use.
PL1780197T3 (en) 5-substituted-2-phenylamino benzamides as mek inhibitors
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
GB0225475D0 (en) Therapeutic agents
EP1232757A4 (en) Remedies for diseases in association with decrease in bone mass
IL154470A0 (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis
HU0102987D0 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
MXPA05008711A (en) Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain.
EP1260221A3 (en) Combination treatment for depression and anxiety
WO2003011309A3 (en) Pharmaceutical composition for treating hypercholesterolaemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP